Status:
RECRUITING
Sensory-Evoked Cortical Gamma Oscillation
Lead Sponsor:
University of Tennessee Medical Center
Conditions:
Alzheimer Disease
Eligibility:
All Genders
60+ years
Phase:
NA
Brief Summary
The purpose of the study is to investigate the efficacy of cortical gamma oscillation on visual sensory processing and cognitive function in Alzheimer's Disease (AD) patients by combining a therapeuti...
Detailed Description
The central hypothesis of the study is that sustained 40Hz gamma oscillatory sensory stimulation therapy will improve cognitive function in patients with AD. The further hypothesis is that the improve...
Eligibility Criteria
Inclusion
- Individuals ages 60 and older with established diagnosis of Alzheimer's Disease as defined by the current consensus criteria for AD (Albert et al, 2011, Jack et al, 2011; McKhann et al, 2011)
- Fluent and literate in English language
- Able to consent for themselves based upon the MacArthur Competence Assessment Tool for Clinical Research
- Patients with a pre-existing positive A(beta)-PET and/or CSF tau/A(beta) markers or willingness to undergo a Lumbar Puncture (LP) with these results
Exclusion
- Not fluent and literate in English
- Severe dementia
- Other medical conditions/neurodegenerative disease that could significantly impair cognitive abilities
- Cardiac pacemakers or any other implants that may not be compatible with MRI
- Cognitively impaired to the point the patient is unable to consent for themselves
- Claustrophobic to the point that medication is required
Key Trial Info
Start Date :
July 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
June 30 2026
Estimated Enrollment :
20 Patients enrolled
Trial Details
Trial ID
NCT05206305
Start Date
July 1 2022
End Date
June 30 2026
Last Update
December 6 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Tennessee Medical Center
Knoxville, Tennessee, United States, 37920